Navigation Links
Treating Alzheimer's disease with Yizhijiannao granules by inhibiting neuronal apoptosis
Date:8/13/2014

Previous studies have shown that Yizhijiannao granule can enhance cognitive performance in Alzheimer's disease patients and Alzheimer's disease-model mice. Further studies revealed that Yizhijiannao granule may exert its therapeutic effect by inhibiting neural cell apoptosis, reducing tau phos-phorylation and relieving neuroinflammation. Dr. Hong Zhu and colleagues who come from Third Xiangya Hospital of Central South University, China treated senescence-accelerated mouse prone 8 mice with Yizhijiannao granule, aiming to identify target-proteins of Yizhijiannao granule that were particularly related to the treatment of Alzheimer's disease. Thirty-seven differential protein spots were found in the temporal lobe area, and finally 10 protein spots were identified. These proteins are separately involved in the regulation of amyloid beta production, oxidative stress, neuroinflammation, regulation of tau phosphorylation, and regulation of neuronal apoptosis. The relevant study has been published in the Neural Regeneration Research (Vol. 9, No. 13, 2014).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related biology news :

1. Toward an oral therapy for treating Alzheimers disease: Using a cancer drug
2. Endocrine Press publishes guide to treating metabolic emergencies
3. Mechanism of cell death unraveled -- perspectives for treating inflammatory diseases
4. Marijuana shows potential in treating autoimmune disease
5. A new approach to treating peanut and other food allergies
6. Grape skin extract may soon be answer to treating diabetes
7. Mouse study points to potentially powerful tool for treating damaged hearts
8. Two researchers known for identifying and treating bubble boy disease honored by March of Dimes
9. Discovery leads to patent for novel method of treating traumatic brain injury
10. Worms and hot baths: Novel approaches to treating autism
11. Old drug may teach new tricks in treating infectious diseases, cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Treating Alzheimer's disease with Yizhijiannao granules by inhibiting neuronal apoptosis
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
Breaking Biology Technology: